Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurobiology of negative reinforcement as a driving force in alcohol addiction.

Neuron·2026
Same author

Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.

Lancet (London, England)·2026
Same author

A ketogenic diet reduces hepatic alcohol metabolism and alcohol consumption in rats.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Potentiation of fentanyl-induced respiratory depression by alcohol is not fully reversed by naloxone.

JCI insight·2026
Same author

Central amygdala <i>Fkbp5</i> expression correlates with faster submission and ethanol self-administration reacquisition: Benztropine reduces ethanol relapse-like reacquisition in stressed rats.

Neurobiology of stress·2026
Same author

Why Opioids Stop Working for Pain: No Free Ride in the Brain.

Annals of internal medicine·2025
Same journal

Abuse Potential and Neurotoxic Effects of the Synthetic Cannabinoid 4F-ABUTINACA Self-Administration in Adult Male Rats.

Addiction biology·2026
Same journal

Longitudinal Cognitive Evolution in Alcohol Use Disorder Patients: Role of Inflammation, Time of Abstinence and Apolipoprotein Profile.

Addiction biology·2026
Same journal

The Interplay Between Sleep Disturbance, Glymphatic Dysfunction and Altered Brain Networks in Internet Gaming Disorder: A Multimodal Neuroimaging Study.

Addiction biology·2026
Same journal

Correction to "Learning Mechanisms in Alcohol Use Disorders".

Addiction biology·2026
Same journal

Abnormal Brain Structural Covariance Networks of Cortical Thickness in Cocaine Use Disorder.

Addiction biology·2026
Same journal

The Orexin System Modulates Stress-Induced Alcohol Preference and Reinstatement in Adolescents: Bioinformatics and Experimental Evidence.

Addiction biology·2026
See all related articles

Related Experiment Video

Updated: Jun 24, 2026

A Procedure to Study the Effect of Prolonged Food Restriction on Heroin Seeking in Abstinent Rats
10:35

A Procedure to Study the Effect of Prolonged Food Restriction on Heroin Seeking in Abstinent Rats

Published on: November 11, 2013

Corticotropin-releasing factor-1 receptor antagonists decrease heroin self-administration in long- but not

Thomas N Greenwell1, Cindy K Funk, Pietro Cottone

  • 1Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, USA.

Addiction Biology
|March 18, 2009
PubMed
Summary
This summary is machine-generated.

Blocking CRF type 1 receptors reduces heroin intake in rats with extended access, suggesting a role for this system in drug dependence. This finding offers potential therapeutic targets for addiction treatment.

More Related Videos

A Procedure to Study Stress-Induced Relapse of Heroin Seeking after Punishment-Imposed Abstinence
08:05

A Procedure to Study Stress-Induced Relapse of Heroin Seeking after Punishment-Imposed Abstinence

Published on: March 23, 2022

A Conditioned Place Preference Protocol for Measuring Incubation of Craving in Rats
04:11

A Conditioned Place Preference Protocol for Measuring Incubation of Craving in Rats

Published on: November 6, 2018

Related Experiment Videos

Last Updated: Jun 24, 2026

A Procedure to Study the Effect of Prolonged Food Restriction on Heroin Seeking in Abstinent Rats
10:35

A Procedure to Study the Effect of Prolonged Food Restriction on Heroin Seeking in Abstinent Rats

Published on: November 11, 2013

A Procedure to Study Stress-Induced Relapse of Heroin Seeking after Punishment-Imposed Abstinence
08:05

A Procedure to Study Stress-Induced Relapse of Heroin Seeking after Punishment-Imposed Abstinence

Published on: March 23, 2022

A Conditioned Place Preference Protocol for Measuring Incubation of Craving in Rats
04:11

A Conditioned Place Preference Protocol for Measuring Incubation of Craving in Rats

Published on: November 6, 2018

Area of Science:

  • Neuroscience
  • Pharmacology
  • Addiction Research

Background:

  • The stress system, specifically the corticotropin-releasing factor (CRF) system, is implicated in drug dependence.
  • Dysregulation of CRF signaling may contribute to the development and maintenance of addiction.

Purpose of the Study:

  • To investigate the impact of CRF type 1 (CRF(1)) receptor antagonists on heroin self-administration.
  • To determine if CRF(1) receptor blockade affects heroin intake differently based on access duration (short vs. long).

Main Methods:

  • Rats were given short (1-hour) or long (8-12 hour) access to intravenous heroin self-administration.
  • Systemic administration of nonpeptide CRF(1) antagonists (MJL-1-109-2 or R121919) was performed.
  • Heroin intake was measured in both short- and long-access conditions.

Main Results:

  • CRF(1) receptor antagonists (MJL-1-109-2 and R121919) significantly reduced heroin self-administration in rats with long access.
  • These antagonists did not alter heroin intake in rats with short access.
  • Selective reduction in first-hour heroin intake was observed in long-access rats, with R121919 also reducing cumulative intake over the session.

Conclusions:

  • Blockade of the CRF-CRF(1) receptor system effectively attenuates increased heroin intake associated with extended drug access.
  • These findings highlight the CRF-CRF(1) receptor system as a potential therapeutic target for mitigating compulsive drug use in addiction.